Soluble Guanylate Cyclase Stimulators in Heart Failure

被引：12
|
作者：
Kansakar, Sajog [1 ]
Guragain, Ashish [1 ]
Verma, Deepak [2 ]
Sharma, Prabhat [1 ,3 ]
Dhungana, Bibek [4 ]
Bhattarai, Bidit [5 ]
Yadav, Sunil [6 ]
Gautam, Ishant [7 ]
机构：
[1] Manipal Coll Med Sci, Internal Med, Pokhara, Nepal
[2] Calif Inst Behav Neurosci & Psychol, Internal Med Family Med, Fairfield, CA USA
[3] Shankarapur Hosp, Internal Med, Kathmandu, Nepal
[4] KIST Med Coll, Internal Med, Lalitpur, Nepal
[5] Venus Hosp, Internal Med, Kathmandu, Nepal
[6] Topa Primary Hlth Ctr, Internal Med, Rajbiraj, Nepal
[7] Bhaktapur Hosp, Internal Med, Bhaktapur, Nepal
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 09期
关键词：
heart failure with reduced ejection fraction (hfref); heart failure with preserved ejection fraction (hfpef); heart failure; guanylate cyclase stimulators; vericiguat; PRESERVED EJECTION FRACTION; NITRIC-OXIDE; VERICIGUAT; PATHOPHYSIOLOGY; CAPACITY; PLACEBO;
D O I：
10.7759/cureus.17781
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Heart failure has a high global burden of morbidity and mortality. Despite significant advances in medical management of heart failure, the prognosis remains poor. This justifies the search for newer therapeutic agents. Recently, soluble guanylate stimulators have demonstrated favorable results in clinical trials. This article aims to summarize the guanylate cyclase signaling pathway, the role of soluble guanylate cyclase stimulators in heart failure, and data from recent clinical trials of these drugs. We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. There appears to be no benefit of these drugs in patients with heart failure with preserved ejection fraction.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Soluble guanylate cyclase (sGC) activator Heart failure therapy
    Gras, J.
    DRUGS OF THE FUTURE, 2018, 43 (08) : 573 - 580
  • [22] Soluble guanylate cyclase: a potential therapeutic target for heart failure
    Gheorghiade, Mihai
    Marti, Catherine N.
    Sabbah, Hani N.
    Roessig, Lothar
    Greene, Stephen J.
    Boehm, Michael
    Burnett, John C.
    Campia, Umberto
    Cleland, John G. F.
    Collins, Sean P.
    Fonarow, Gregg C.
    Levy, Phillip D.
    Metra, Marco
    Pitt, Bertram
    Ponikowski, Piotr
    Sato, Naoki
    Voors, Adriaan A.
    Stasch, Johannes-Peter
    Butler, Javed
    HEART FAILURE REVIEWS, 2013, 18 (02) : 123 - 134
  • [23] Soluble guanylate cyclase: a potential therapeutic target for heart failure
    Mihai Gheorghiade
    Catherine N. Marti
    Hani N. Sabbah
    Lothar Roessig
    Stephen J. Greene
    Michael Böhm
    John C. Burnett
    Umberto Campia
    John G. F. Cleland
    Sean P. Collins
    Gregg C. Fonarow
    Phillip D. Levy
    Marco Metra
    Bertram Pitt
    Piotr Ponikowski
    Naoki Sato
    Adriaan A. Voors
    Johannes-Peter Stasch
    Javed Butler
    Heart Failure Reviews, 2013, 18 : 123 - 134
  • [24] Activation mechanism of human soluble guanylate cyclase by stimulators and activators
    Liu, Rui
    Kang, Yunlu
    Chen, Lei
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [25] Is there a role for soluble guanylate cyclase stimulators in acute pulmonary embolism?
    Appavu, Samuel K.
    CRITICAL CARE MEDICINE, 2011, 39 (12) : 2773 - 2774
  • [26] Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease
    Kosmac, Kate
    Ismaeel, Ahmed
    Kim-Shapiro, Daniel B.
    McDermott, Mary M.
    CIRCULATION RESEARCH, 2023, 132 (01) : 49 - 51
  • [27] Activation mechanism of human soluble guanylate cyclase by stimulators and activators
    Rui Liu
    Yunlu Kang
    Lei Chen
    Nature Communications, 12
  • [28] Soluble guanylate cyclase stimulators and their potential use: a patent review
    Sandner, Peter
    Vakalopoulos, Alexandros
    Hahn, Michael G.
    Stasch, Johannes-Peter
    Follmann, Markus
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2021, 31 (03) : 203 - 222
  • [29] Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs
    Tawa, Masashi
    Nakagawa, Keisuke
    Ohkita, Mamoru
    HYPERTENSION RESEARCH, 2025, : 1458 - 1470
  • [30] Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction
    Abuelazm, Mohamed T.
    Attia, Abdelrahman
    Abdelnabi, Mohamed
    Jafar, Uzair
    Almaadawy, Omar
    Elzeftawy, Mohamed A.
    Mahmoud, Abdelrahman
    Albakri, Khaled
    Abdelazeem, Basel
    EGYPTIAN HEART JOURNAL, 2024, 76 (01):
12345